Customize
Quick Links
Specialties

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Incyte Corporation.

Year in Review™: Clinical Impact of Immunotherapies in the Treatment of Cancer PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap



1 of 3

The Rapid Rise of Immunotherapy in Bladder Cancer

Year in Review™: Clinical Impact of Immunotherapies in the Treatment of Cancer highlighted key clinical data with immune checkpoint inhibitors that emerged in 2016. The program co-chairs, Roy S. Herbst, MD, PhD, and Jason J. Luke, MD, FACP, along with faculty Arjun Balar, MD, and Tanguy Seiwert, MD, discussed key clinical data leading to the approval of anti–PD-1 and anti–PD-L1 antibodies in multiple tumor types.

This first of 3 PER Pulse™ Recaps from this Year in Review™ focuses on recent developments in immunotherapy for patients with advanced bladder cancer:

To view the videos and expert commentary for this edition of Year in Review™, please visit www.gotoper.com.



2 of 3
PER Pulse™ Recap

New Frontiers for Single-Agent and Combination Immunotherapy in Lung Cancer

Year in Review™: Clinical Impact of Immunotherapies in the Treatment of Cancer highlighted key clinical data with immune checkpoint inhibitors that emerged in 2016. The program co-chairs, Roy S. Herbst, MD, PhD, and Jason J. Luke, MD, FACP, along with faculty Arjun Balar, MD, and Tanguy Seiwert, MD, discussed key clinical data leading to the approval of anti–PD-1 and anti–PD-L1 antibodies in multiple tumor types.

This second of 3 PER Pulse™ Recaps from this Year in Review™ focuses on new approaches and settings with immunotherapy in non–small-cell lung cancer (NSCLC).

To view the videos and expert commentary for this edition of Year in Review™, please visit www.gotoper.com.


3 of 3
PER Pulse™ Recap

Current and Future Directions for Immunotherapy in Cutaneous Malignancies and Head and Neck Cancer

Year in Review™: Clinical Impact of Immunotherapies in the Treatment of Cancer highlighted key clinical data with immune checkpoint inhibitors that emerged in 2016. The program co-chairs, Roy S. Herbst, MD, PhD, and Jason J. Luke, MD, FACP, along with faculty Arjun Balar, MD, and Tanguy Seiwert, MD, discussed key clinical data leading to the approval of anti–PD-1 and anti–PD-L1 antibodies in multiple tumor types.

This third of 3 PER Pulse™ Recaps from this Year in Review™ focuses on recent developments in immunotherapy for patients with melanoma, Merkel cell carcinoma (MCC), and head and neck cancer:

To view the videos and expert commentary for this edition of Year in Review™, please visit www.gotoper.com.

  • Prior to May 2016, there was a decades-long lack of new therapies for patients with advanced bladder cancer.
  • During the period including May 2016-May 2017, at least 5 immune checkpoint inhibitors (atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab) received approval. They are summarized in the Table below.
    • In 2015, the first approvals for immunotherapy in advanced NSCLC occurred, with single-agent approvals for nivolumab and pembrolizumab, both anti–PD-1 antibodies, in patients with pretreated disease. Recent data have demonstrated the potential of immunotherapy in additional settings, as well as the activity of combination approaches.
    • In the first-line setting, single-agent pembrolizumab demonstrated superior efficacy compared with chemotherapy in patients with PD-L1–positive NSCLC (≥50%), leading to approval in October 2016. Subsequently, the addition of pembrolizumab to carboplatin/pemetrexed yielded a superior response and progression-free survival compared with chemotherapy alone in patients with nonsquamous NSCLC, leading to accelerated approval in May 2017.
    • Several combinations are being investigated in the first-line setting, including immunotherapy plus immunotherapy and immunotherapy plus chemotherapy (Table).
    • In patients with previously treated NSCLC, the anti–PD-L1 antibody atezolizumab was approved in October 2016, joining nivolumab and pembrolizumab as therapeutic options in this setting.
    • In May 2017, it was announced that the anti–PD-L1 antibody durvalumab significantly improved progression-free survival compared with placebo in patients with unresectable stage III NSCLC who had not progressed after concurrent chemoradiation therapy.
    • The phase 3 CheckMate 067 trial initially showed superior progression-free survival with nivolumab/ipilimumab or single-agent nivolumab compared with single-agent ipilimumab in patients with advanced, previously untreated melanoma, which supported accelerated approval in January 2016. An updated analysis with ≥28 months of follow-up also showed superior overall survival (OS) with both nivolumab-containing arms compared with single-agent ipilimumab.
    • In MCC, the anti–PD-L1 antibody avelumab received accelerated approval in March 2017 for patients ≥12 years, including those who have not received prior chemotherapy, and was the first immune checkpoint inhibitor to be approved for this disease. Pembrolizumab has also demonstrated activity in patients with MCC and no prior systemic therapy.
    • For patients with metastatic head and neck cancer whose disease progresses after platinum-based chemotherapy, 2 immune checkpoint inhibitors were approved in November 2016. Pembrolizumab received accelerated approval based on data from the phase 1b KEYNOTE-012 trial and nivolumab received full approval based on superior OS in comparison with methotrexate, docetaxel, or cetuximab in the phase III CheckMate 141 trial.
    • Several ongoing phase III trials are investigating single-agent and combination approaches with immunotherapy as first-line therapy for patients with recurrent/metastatic head and neck cancer.
      • KESTREL: durvalumab ± tremelimumab versus cetuximab/platinum/5-FU
      • KEYNOTE-048: pembrolizumab ± platinum/5-FU versus cetuximab/platinum/5-FU
      • CheckMate 651: nivolumab/ipilimumab versus cetuximab/platinum/5-FU
PER® Practice Pulse
Practice Pattern Questions
How often do you attend society oncology/hematology meetings? (ASCO, ASH, SABCS)
Practice Pattern Questions
What is the most significant barrier to implementing new information in your clinical practice?






Become a Member

Forgot Password?
Filter By